L 783281: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3013166 |
| SCHEMBL ID | 304445 |
| MeSH ID | M0304948 |
| Synonym |
|---|
| HMS3268I16 |
| dmaq-b1 |
| 2-[2-(1,1-dimethylallyl)-1h-indol-3-yl]-3,6-dihydroxy-5-[7-(3-methylbut-2-enyl)-1h-indol-3-yl]-1,4-benzoquinone |
| 2,5-cyclohexadiene-1,4-dione, 2-[2-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl]-3,6-dihydroxy-5-[7-(3-methyl-2-butenyl)-1h-indol-3-yl]- |
| NCGC00025307-01 |
| tocris-1819 |
| l-783,281 |
| daq b1 |
| demethylasterriquinone b1 |
| l 783281 |
| 2,5-dihydroxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[7-(3-methylbut-2-enyl)-1h-indol-3-yl]cyclohexa-2,5-diene-1,4-dione |
| l783281 |
| 78860-34-1 |
| l-783281 |
| SCHEMBL304445 |
| 2-[2-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl]-3,6-dihydroxy-5-[7-(3-methyl-2-butenyl)-1h-indol-3-yl]-2,5-cyclohexadiene-1,4-dione |
| AKOS024456800 |
| SR-01000597541-1 |
| sr-01000597541 |
| XMGNJVXBPZAETK-UHFFFAOYSA-N |
| 2,5-dihydroxy-3-(7-(3-methylbut-2-en-1-yl)-1h-indol-3-yl)-6-(2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl)cyclohexa-2,5-diene-1,4-dione |
| demethylasterriquinone b 1; dimethylasterriquinone |
| EX-A4908 |
| unii-f6582h6jqw |
| AMY42295 |
| NCGC00025307-02 |
| 2566744-46-3 |
| 2,5-cyclohexadiene-1,4-dione, 2-(2-(1,1-dimethyl-2-propenyl)-1h-indol-3-yl)-3,6-dihydroxy-5-(7-(3-methyl-2-butenyl)-1h-indol-3-yl)- |
| F6582H6JQW , |
| dimethylasterriquinone |
| 2,5-cyclohexadiene-1,4-dione, 2-(2-(1,1-dimethyl-2-propen-1-yl)-1h-indol-3-yl)-3,6-dihydroxy-5-(7-(3-methyl-2-buten-1-yl)-1h-indol-3-yl)- |
| CS-0028912 |
| HY-107586 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, PAPAIN | Carica papaya (papaya) | Potency | 4.4668 | 0.3000 | 12.5348 | 31.6228 | AID2161 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 19.9526 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 4.4668 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 7.9433 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 7.9433 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 10.0000 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 24.1969 | 0.0020 | 14.6779 | 39.8107 | AID1476; AID1478; AID2158 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 69.8577 | 0.0316 | 37.5844 | 354.8130 | AID504865; AID540327 |
| TDP1 protein | Homo sapiens (human) | Potency | 13.3359 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 26.9680 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 0.0063 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.4435 | 31.6228 | AID924 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 28.1838 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 1.2589 | 0.0025 | 5.8400 | 31.6228 | AID899 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 7.9433 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 17.7828 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 15.8489 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 1.4125 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 25.1189 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 39.8107 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 20.6903 | 0.0063 | 8.2350 | 39.8107 | AID881; AID883 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Oryctolagus cuniculus (rabbit) | IC50 (µMol) | 15.0000 | 0.2000 | 0.2000 | 0.2000 | AID292160 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | Kd | 7.2000 | 7.2000 | 7.2000 | 7.2000 | AID292161 |
| Insulin receptor | Homo sapiens (human) | EC50 (µMol) | 5.0000 | 1.0000 | 3.0000 | 5.0000 | AID91685 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID93465 | Percent insulin like growth factor receptor(IGFIR) activity at 30 uM | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. |
| AID155188 | Percent platelet derived growth factor receptor (PDGFR) activity at 30 uM | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. |
| AID67287 | Percent epidermal growth factor receptor (EGFR) activity at 30 uM | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. |
| AID93071 | Percent activation of insulin receptor in CHO cells by 10 uM of compound | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | The basal SAR of a novel insulin receptor activator. |
| AID93074 | Ability to activate the insulin receptor compared to that of lead structure 1 expressed as X/1 | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | The basal SAR of a novel insulin receptor activator. |
| AID292161 | Binding affinity to GAPDH in human erythrocytes | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. |
| AID292160 | Binding affinity to GAPDH in rabbit muscle | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. |
| AID91685 | Activation of human insulin receptor tyrosine kinase (IRTK) | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 21 (70.00) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 4 (12.90%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (87.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||